Nemis Technologies has successfully closed its seed financing round and raised 3 million francs, it was reported in a press release. The company based in Dübendorf is a joint venture between Biosynth AG from Staad SG and Ramot, which operates as a technology transfer company of the Tel Aviv University.
Nemis Technologies is developing diagnostic kits for the faster detection of pathogenic bacteria. These solutions are intended for use in the areas of food safety, hospital and clinical applications and water treatment. The AquaSpark platform forms the basis of these diagnostics solutions, having originally been developed at the Tel Aviv University and licensed by Ramot. AquaSpark enables highly sensitive chemiluminescence probes to be created for research and diagnostic applications. With these probes, pathogenic bacteria are made visible more quickly than with standard methods.
Roger Meier, Chairman of the Board of Nemis Technologies, is pleased to welcome new investors. The funds raised will enable the company to advance its technology to prototypes and towards industrialisation.
More News
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com